SERNIVO (betamethasone dipropionate) · PRIMUS PHARMS
Sernivo (betamethasone dipropionate) is a topical corticosteroid spray indicated for the treatment of mild to moderate plaque psoriasis in adults 18 years of age and older. It is used to manage the inflammatory and pruritic (itching) manifestations of the condition.
How SERNIVO Works
Betamethasone dipropionate is a corticosteroid that influences cellular signaling, immune function, and protein regulation. While the exact mechanism of action in the treatment of plaque psoriasis is not fully established, it is recognized for its anti-inflammatory, antipruritic, and vasoconstrictive properties.
Details
- Status
- Prescription
- First Approved
- 2016-02-05
- Patent Cliff
- 2030
- Routes
- TOPICAL
- Dosage Forms
- SPRAY
SERNIVO Approval History
What SERNIVO Treats
1 indicationsSERNIVO is approved for 1 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.
SERNIVO Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to SERNIVO
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT03999229 | STUDY20221492 5R01HL126900 | Ph 1 | recruiting | S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion |
| NCT06332612 MROSF | 8420224AROM | Ph 1, Ph 2 | completed | Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
SERNIVO FDA Label Details
Indications & Usage
FDA Label (PDF)Betamethasone dipropionate cream (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. Betamethasone dipropionate cream (augmented), 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.
Pro Intelligence Preview
Deep insights for SERNIVO
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2030
- • 7 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.